SCHEDULE: Wellington Management Holds 9.1% Stake in Immunocore

Wellington Management Group LLP and its affiliates report a continued 9.1% beneficial ownership stake in Immunocore Holdings plc common stock.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, collectively hold a significant stake in Immunocore Holdings plc.
• The aggregate amount beneficially owned by these reporting persons is 4,515,524 shares of Common Stock.
• This represents 9.1% of the class of Immunocore Holdings plc's Common Stock.
• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each report shared voting power over 4,372,335 shares and shared dispositive power over 4,515,524 shares.
• Wellington Management Company LLP reports shared voting power over 4,358,802 shares and shared dispositive power over 4,395,729 shares, representing 8.9% of the class.
• The securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Clients of Wellington Investment Advisers are the record owners, with Vanguard Health Care Fund identified as a client holding more than five percent of the class.

Sentiment

Score: 7

Explanation: The filing indicates a significant and continued stake by a major institutional investor, which is generally viewed positively as a sign of confidence, although it does not provide new performance data.

Positives

• A major institutional investor, Wellington Management, maintains a significant 9.1% stake in Immunocore Holdings plc, indicating continued confidence in the company.
• The holding is for investment purposes in the ordinary course of business, not for control, suggesting a long-term investment perspective.

Risks

• The filing itself does not detail specific risks related to Immunocore Holdings plc's operations or financial health, as it is a beneficial ownership report.

Future Outlook

NA

Industry Context

The filing indicates continued institutional investment interest in the biotechnology and pharmaceutical sector, specifically in Immunocore Holdings plc, by a prominent asset manager.

Stakeholder Impact

• Shareholders may view the continued significant stake by Wellington Management as a positive signal of institutional confidence in Immunocore Holdings plc.

Key Dates

Recommendation

The filing is a routine disclosure of a significant beneficial ownership stake by a major institutional investor. While the continued presence of a large, reputable investor like Wellington Management is generally a positive signal, this filing alone does not provide new fundamental information or catalysts to warrant a 'buy' or 'sell' recommendation. It suggests a 'hold' position, reflecting ongoing institutional confidence without new performance data.

Keywords

Immunocore Holdings plc, Wellington Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals